ID   10C5.6
AC   CVCL_C9FP
DR   ABCD; ABCD_AK558
DR   Wikidata; Q123030202
RX   Patent=US8231877;
RX   PubMed=9631008;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was developed into a therapeutic mAB known as Zanolimumab to be used in the treatment of rheumatoid arthritis, psoriasis, melanoma and cutaneous and peripheral T-cell lymphoma.
CC   Doubling time: 19 hours (PubMed=9631008).
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P01730; Human CD4.
CC   Miscellaneous: As the immunized splenic B-cells are from humanized transgenic HC2/KCo5/JHD/JCkappaD mice the produced mAB is of human origin.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   Patent=US8231877;
RA   Lonberg N., Kay R.M., Fishwild D.M.;
RT   "Heterologous antibodies which bind human CD4.";
RL   Patent number US8231877, 31-Jul-2012.
//
RX   PubMed=9631008; DOI=10.1038/nbt0796-845;
RA   Fishwild D.M., O'Donnell S.L., Bengoechea T., Hudson D.V., Harding F.,
RA   Bernhard S.L., Jones D., Kay R.M., Higgins K.M., Schramm S.R.,
RA   Lonberg N.;
RT   "High-avidity human IgG kappa monoclonal antibodies from a novel
RT   strain of minilocus transgenic mice.";
RL   Nat. Biotechnol. 14:845-851(1996).
//